Alkermes releases nine-month data as OX2R race heats up

Alkermes has released long-term data for its OX2R agonist, which could face two other drugs of the same mechanism of action on the market. Alkermes has released long term data for its OX2R agonist which could face two other drugs of the same mechanism of action on the market. Alkermes has released nine-month data for its oral OX2R agonist in NT1 and NT2. Credit: fizkes / Shutterstock.com Alkermes’ oral, selective orexin 2 receptor (OX2R) agonist has shown continued benefit nine months after the start of treatment in patients with narcolepsy types 1 (NT1) and 2 (NT2). In an interim analysis…

Source: Clinical Trials Arena